BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.57 Average Target Price from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $15.57.

BCRX has been the topic of several research reports. Wedbush began coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of BioCryst Pharmaceuticals in a research note on Thursday. Evercore ISI increased their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $11.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday. Finally, JMP Securities reiterated a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st.

Institutional Trading of BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company boosted its holdings in shares of BioCryst Pharmaceuticals by 40.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock worth $2,274,000 after buying an additional 86,571 shares during the last quarter. Vanguard Group Inc. boosted its stake in BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after acquiring an additional 1,583,826 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after acquiring an additional 375,890 shares during the period. Teacher Retirement System of Texas increased its stake in shares of BioCryst Pharmaceuticals by 25.1% during the 4th quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company’s stock worth $438,000 after purchasing an additional 11,711 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock worth $14,890,000 after purchasing an additional 91,998 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Up 6.4 %

Shares of BioCryst Pharmaceuticals stock opened at $6.82 on Tuesday. The company has a market cap of $1.43 billion, a P/E ratio of -11.18 and a beta of 1.75. The business has a 50-day moving average price of $7.96 and a two-hundred day moving average price of $7.74. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. The firm’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period last year, the business posted $0.28 earnings per share. Equities research analysts forecast that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.